Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm

Annika Scheffold1 · Stephan Stilgenbauer1,2

Published online: 5 February 2020 © The Author(s) 2020

Abstract
Purpose of Review Over the last years, targeted anticancer therapy with small molecule inhibitors and antibodies has much replaced chemoimmunotherapy, which has been the gold standard of care for patients with chronic lymphocytic leukemia (CLL). Here we give an overview of novel targeted agents used in therapy of chronic lymphocytic leukemia, as well as efforts to overcome resistance development, focusing on approved drugs since they gained high relevance in clinical practice.

Recent Findings Novel agents moved to the forefront as a treatment strategy of CLL due to their outstanding efficacy, almost irrespectively of the underlying genetic features. Inhibition of Bruton’s tyrosine kinase (BTK), a key molecule in the B cell receptor pathway, achieved dramatic efficacy even in poor-risk and chemo-refractory patients. Further success was accomplished with venetoclax, which specifically inhibits anti-apoptotic BCL2 and induces apoptosis of CLL cells.

Summary Inhibition of BTK or BCL2 is very effective and induces prolongation of progression-free and overall survival. Approved combination treatments such as venetoclax or ibrutinib with obinutuzumab show high responses rates and long remission durations. However, evolution and selection of subclones with continuous treatment leads to resistance towards these novel drugs and disease relapse. Hence, comparison of sequential treatment with combinations and discontinuation of therapy are important aspects which need to be investigated.

Keywords Chronic lymphocytic leukemia · BCR signaling · BTK inhibitor · Venetoclax · BCL2 inhibitors

Introduction
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults and mainly affects the elderly [1]. CLL is a B cell malignancy, where clonal CD5+CD19+CD23+ B cells accumulate in peripheral blood and infiltrate secondary lymphoid organs such as lymph nodes, spleen, and bone marrow [2]. The disease is highly heterogeneous clinically mostly due to hypermutations of the immunoglobulin heavy-chain genes (IGHV), genomic aberrations, and recurrent gene mutations which associate with the clinical course [3, 4]. The mechanisms underlying CLL pathogenesis are not fully resolved. Allogenic stem cell transplantation is still the only curative therapy, although limited to a small subset of young and fit patients [5]. For the last 10 years, chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) has been the most effective treatment but its success is limited by comorbidities, age, and fitness of the patients [6–8]. However, treatment of patients with high-risk del(17p) or TP53 mutations have shown poor outcome [9–11].

Recent scientific advances in understanding the biology of CLL evolved in the development of novel therapeutic agents. Small molecule inhibitors targeting key survival mechanisms revolutionized therapy and showed unparalleled effects in patients irrespective of their genetic aberrations. The novel agents led to a paradigm change in patient care from treatment with unspecific DNA damaging agents to “targeted therapy.”
Chemoimmunotherapy in CLL

The CD20 antigen is expressed on the surface of mature B cells and is one of the most successful targets in treatment of B cell malignancies. Monoclonal antibodies are widely used to deplete B cells in cancers or autoimmune diseases. The first CD20 antibody was rituximab, which has been FDA (US Food and drug administration)-approved in 1998. Several modes of action of rituximab are currently known such as complement-dependent cytotoxicity (CDC), opsonization of macrophages inducing antibody-dependent cell-mediated cytotoxicity (ADCC), and direct killing by apoptosis to a lower extent [12]. Additionally, CD20 receptor colocalizes with the B cell receptor participating in its activation and signaling. Despite that, the exact mode of action of rituximab still remains unclear. If rituximab was combined with fludarabine and cyclophosphamide, progression-free survival (PFS) and overall survival (OS) were significantly improved [13]. In the CLL8 trial, the FCR (fludarabine-cyclophosphamide-rituximab) group had a PFS of 56.8 months compared with 32.9 months in the FC (fludarabine-cyclophosphamide) arm. Here, the median OS in the FCR arm was not reached in comparison with 86 months in the FC arm [8]. IGHV-mutated patients had most benefit from FCR. However, chemoimmunotherapy is less effective with negative impact on PFS and OS in patients with unmutated IGHV, mutated TP53 and del(17p), del(11q), and some gene mutations such as NOTCH1, SF3B1, and BIRC3 [3, 7].

Ofatumumab is a humanized anti-CD20 monoclonal antibody which targets a different epitope than rituximab resulting in enhanced activation of CDC and similar activation of ADCC and apoptosis [14]. Ofatumumab was approved as a single agent in fludarabine refractory CLL, as well as in combination with fludarabine and cyclophosphamide for refractory CLL or with chlorambucil or bendamustine for treatment-naive patients. Good tolerability was shown in elderly patients with a median PFS of 22.4 months (ofatumumab and chlorambucil; COMPLEMENT-1 trial) versus 13.1 months (chlorambucil monotherapy) [15]. The COMPLEMENT-2 trial demonstrated an increased PFS of relapsed patients from 18.8 months (FC) to 28.9 months (FCO) when adding ofatumumab to the FC treatment [16]. Similar to treatment with rituximab, patients with NOTCH1 mutations benefited less. In spite of everything, the use of ofatumumab is suggested in earlier course of disease, since a phase IV study in heavily pretreated patients demonstrated limited efficacy and low numbers of responses [17].

On the contrary, obinutuzumab (GA101) is a recombinant type II anti-CD20 and immunoglobulin G1 Fc-optimized monoclonal antibody, which induces CDC and direct cell death upon binding to CD20 depending on actin reorganization and lysosome involvement [18]. A successful phase I trial showed a response rate of 62% demonstrating activity of obinutuzumab in heavily pretreated patients [19]. In the phase III CLL11 study, obinutuzumab was combined with chlorambucil (clb) and compared with rituximab-chlorambucil and chlorambucil monotherapy. Obinutuzumab-clb was superior to rituximab-clb and clb-monotherapy, more frequently associated with a negative MRD (minimal residual disease, defined as less than 1 CLL cell in 10,000 leukocytes) and prolonged PFS (median PFS 27.6 and 16.3 months vs. 11.1 months, respectively) [20]. Since obinutuzumab showed higher potency, equal tolerability and rarely enriched adverse effects than rituximab, it was FDA-approved in 2013 for untreated CLL patients in combination with chlorambucil who are not eligible for a high intensive therapy.

Infection rates of obinutuzumab were similar to rituximab, but more severe infusion-related side effects were observed. Nevertheless, rituximab is the only CD20 antibody which is broadly approved for combined use, while obinutuzumab is currently approved in combination with clb or with venetoclax (see below).

Targeting BCR Signaling

B cell receptor (BCR) signaling is essential for CLL cells. Several novel agents target molecules of the BCR pathway and are effective even in high-risk CLL. In 2014, the FDA approved ibrutinib, an orally bioavailable BTK (Bruton’s tyrosine kinase) inhibitor, as monotherapy in relapsed/refractory CLL (R/R). The mode of action of ibrutinib operates via specific covalent binding to the cysteine 481 in the active site of the BTK enzyme. Binding to BTK inhibits downstream signaling such as MAPK, PI3K, and NF-kB, and reduces migration and proliferation of the tumor cell [21]. In patients, ibrutinib induces lymphocytosis with an asymptomatic increase of tumor cells in the peripheral blood, whereas rapid shrinkage of lymph nodes and spleen is observed. Lymphocytosis alone must not be correlated with disease progression and usually resolves within a few months of therapy [22]. Approval of ibrutinib was based on a phase Ib/II trial, where 85 heavily pretreated R/R patients reached a PFS of 75% and OS of 83% after 26 months [23]. Intriguingly, the response was independent of genomic risk factors, prior therapies, or the presence of del(17p). A 5-year follow-up of an extended patient collective showed an overall response of 92% in treatment-naive patients and 89% in R/R patients, respectively. The PFS rate of ibrutinib monotherapy was 92% in treatment-naive patients and 44% in R/R patients, while the OS rate was 92% and 60%. Hematological adverse
events (AEs) such as grade 3 cytopenia, neutropenia, and thrombocytopenia decreased over time [24].

The phase III RESONATE study compared single-agent ibrutinib and ofatumumab in high-risk relapsed patients. Follow-up after only 19 months showed a significantly longer PFS in the ibrutinib arm with 91% of patients attaining a response. The PFS at 24 month was 74%. Long-term follow-up reported a continuous response to ibrutinib, which was increasing over time. Median duration of ibrutinib was 41 months, with 46% remaining on treatment at a median follow-up of 44 months [25].

The phase III HELIOS trial compared ibrutinib and bendamustine with rituximab in treated CLL without del(17p). At an observation time of 18 months, BR + ibrutinib were superior with a PFS of 79% in comparison with 24% in the BR + placebo group. Impressively, the PFS at 36 months was 68% vs 13.9% (Fig. 1a). Overall survival at 36 months was 81.6% vs. 72.9%, (Fig. 1b) [26].

In the front line treatment setting, the RESONATE-2 phase III study compared ibrutinib vs. chlorambucil in elderly, untreated patients. A superior response to ibrutinib was demonstrated with a PFS of 24 months, whereas the median was not reached under treatment with chlorambucil as compared with 18.9 months under ibrutinib and an OS of 85% vs. 98.9%, respectively [27].

More recent clinical phase III trials demonstrated superiority of ibrutinib in comparison with chemoimmunotherapy (ECOG-ACRIN E1912, Alliance A041202, iILLUMINATE) [28–30]. The phase III E1912 trial demonstrated superior PFS and OS for ibrutinib + rituximab in comparison with FCR in a large cohort of 510 untreated young and fit patients without del(17p) [28]. Alliance A041202 compared ibrutinib with ibrutinib + rituximab and bendamustine + rituximab (BR). Ibrutinib monotherapy or ibrutinib + rituximab prolonged PFS in comparison with BR as a frontline regimen. Of note, the addition of rituximab did not add a benefit in comparison with ibrutinib monotherapy [29]. With iILLUMINATE, the chemotherapy free combination of ibrutinib + obinutuzumab was validated to be superior in naïve patients compared with chlorambucil + obinutuzumab [30].

Based on these extensive clinical trial data, ibrutinib is the preferred option as first line therapy in old and young patients. One disadvantage of the regimen is the need for continuous therapy, which may stimulate resistance generation due to continued selection pressure.

Despite its initial efficacy, patients relapse under ibrutinib therapy. Interestingly, analysis of tumor cells of patients who progressed under ibrutinib therapy revealed specific mutations in BTK at position 481. Of importance, the C481S mutation of BTK conferred resistance by preventing the covalent binding of ibrutinib to its target cysteine 481 in BTK [31, 32]. Furthermore, several mutations were identified in PLCG2, which functions downstream of BTK. The gain-of-function mutations in PLCG2 induce hyperreactive BCR signaling mediated by RAC2 and loss of dependence on BTK [33]. Sequencing of relapsed patient cells uncovered that 85% of all patients which relapse during ibrutinib treatment, carried a BTK or PLCG2 mutation. The mutations were already detectable early after a median of 9.4 months of ibrutinib treatment. This knowledge is essential to avoid early resistance and could help to decide a possible switch of interventions [34].

![Fig. 1](https://example.com/fig1.png)
PI3K Inhibitors Idelalisib and Duvelisib

The phosphoinositide 3-kinase (PI3K) delta inhibitor idelalisib targets BCR signaling in CLL cells. It was FDA-European Medicines Agency (EMA)-approved in 2014 for patients with refractory CLL. The approval was based on a phase III study in which idelalisib and rituximab significantly improved PFS and OS [35]. Idelalisib also showed efficacy in patients with del(17p) or TP53 mutations. Furthermore, interim results of a phase III trial demonstrated that the combination of bendamustine, rituximab, and idelalisib significantly enhanced PFS in patients with R/R CLL in comparison with BR + placebo (median PFA 20.8 vs. 11.1 months) [36]. Very recent updates of the Gilead 116/117 trial report improved efficacy of rituximab/idelalisib compared with rituximab monotherapy: an overall response rate (ORR) of 85.5% after 20.3 months of follow-up. Improved OS was the greatest among patients with del(17p) or TP53 mutation. Additionally, IGHV unmutated cases showed similar efficacy. In contrast, long-term exposure to idelalisib increased adverse effects, especially grade 3 diarrhea, colitis, and pneumonitis [37].

At the beginning of 2018, the approval of idelalisib in combination with rituximab and bendamustine for R/R CLL was withdrawn because of toxicity concerns. Black boxed warnings on idelalisib drug treatment were implemented due to fatal or severe hepatotoxicity (11–18%), diarrhea/colitis (14–19%), pneumonitis (4%), infections (21–36%), intestinal perforation, and transaminitis (54% grade 3) [38]. An interim analysis of three earlier-stage clinical trials demonstrated decreased overall survival in the idelalisib arms due to severe infections with PJP (pneumocystis jiroveci fungus) and CMV (cytomegalovirus). The EMA mandated additional safety measurements, PJP prophylaxis and CMV monitoring. Preclinical research data demonstrate that PI3K inhibition can modulate the effect in regulatory T cells on tumor cells, supporting the effect of PI3Kδ inhibitors. Nonetheless, CD8+ T cell function was decreased upon PI3K inhibition which might explain increased susceptibility for infections [39]. Acquired resistance to idelalisib treatment has been observed in humans, although no unique recurrent mutation was identified [40]. Preclinical data show that resistance to PI3Kδ inhibition does not rely on a unique mutation, though resistance to PI3Kδ inhibition induces a relevant activation of IGF1R, resulting in enhanced MAPK signaling [41].

Since idelalisib treatment appears to be associated with a higher rate of adverse effects than ibrutinib or venetoclax, idelalisib is not selected as the first choice for relapsed/refractory patients and remains reserved for higher lines of therapy and for patients not suitable for other therapeutic options.

Duvelisib (IPI-145) is the second FDA-approved PI3K inhibitor, targeting γ and δ isoforms. Preclinical studies demonstrate greater activity of inhibition of both isoforms γ and δ than PI3Kδ alone [42]. The phase III DUO trial compared duvelisib monotherapy with ofatumumab in patients with R/R CLL. Patients treated with duvelisib had significantly better PFS and ORR. Serious adverse effects were reported in 67% of patients treated with duvelisib. Adverse effects grade 3 occurred in 87% of the duvelisib treated patients compared with 48% in the ofatumumab-treated arm. Pneumonia, infections, and diarrhea were the most frequent [43]. Based on the DUO trial, duvelisib was FDA-approved for R/R CLL after two prior lines of therapy in 2018.

Targeting B Cell Lymphoma 2 (BCL2)

A novel treatment principle was introduced by targeting B cell lymphoma 2 (BCL2) using the BH3 mimetics, which cause immediate apoptosis of tumor cells. BCL2 family proteins play a major role in the regulation of cell death and are highly conserved. The BCL2 family is clustered into three main functional groups, the pro-survival and anti-apoptotic proteins BCL2, MCL-1, BCL-xL, and BCL-w [44–46], the multi-BH domain pro-apoptotic proteins BAX and BAK, and the pro-apoptotic BH3-only proteins BIM, tBID; BAD, PUMA; NOXA, and HRK [47–49] that trigger and execute the “suicidal” cell death. In healthy cells, the balance between cell survival and cell death requires dynamic binding interactions between pro-apoptotic and anti-apoptotic proteins. CLL cells overexpress anti-apoptotic BCL2. Overexpression of BCL2 is caused by various mechanisms. The most common cytogenetic abnormality is the del(13q14), the minimally deleted region of which includes the BCL2 repressors and microRNAs 15 and 16 [50]. Moreover, hypomethylation of BCL2 in CLL also contributes to BCL2 upregulation due to epigenetic dysregulation [51, 52]. On the other hand, defects in expression of pro-apoptotic members result in a loss of the tumor suppressive function and lead to an imbalance between pro-and anti-apoptotic BCL2 family proteins. Homozygous deletions or inactivating mutations of BAX and BID [53, 54] or defective expression of BID and PUMA due to loss of p53 function also tip the balance towards anti-apoptotic proteins [55, 56].

BCL2 can be selectively targeted with venetoclax which is a novel, orally bioavailable BH3 mimic. Venetoclax shows high efficacy in particular in the treatment of CLL, but preliminarily also in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). BH3 mimetics bind to the hydrophobic groove of BCL2 inducing apoptosis. The precursor molecule of venetoclax, ABT-737 had a binding potential to BCL2, BCL-xL, and BCL-w, and showed activity in vitro. Navitoclax (ABT-263), an orally available derive, showed promising efficacy in CLL patients [57]; however, strong inhibition of BCL-xL induced a rapid decrease in circulating...
platelets and thrombocytopenia which arrested its clinical development.

Venetoclax was approved by the FDA and EMA in December 2016 for patients with previously treated CLL with del(17p13) and patients failing B cell receptor signaling inhibitors (EMA only), or who carry a TP53 mutation and are refractory to chemoimmunotherapy and BCR inhibitors recruited in the phase II M13-982 and M14-032 trials [58•]. M13–982 was a pivotal phase II clinical trial, enrolling relapsed/refractory CLL patients with del(17p). In this multicenter open-label study, 158 patients were treated with venetoclax with a weekly dose ramp up from 20 to 400 mg over 4 weeks (20, 50, 100, 200, and 400 mg, due to the risk of tumor lysis syndrome (TLS), see below) which was continued until disease progression. At a median time of 26.6 months on study, 77% of all patients had achieved an ORR (122 of 158 patients). The 24-month estimate for ongoing response was 66% (95% CI, 55% to 74%, Fig. 2a); the 24-month estimate of PFS and OS were 54% (95% CI, 45% to 62%, Fig. 2b), and 73% (95% CI, 65% to 79%, Fig. 2c), respectively. Estimated PFS of patients with complete remission (CR) or incomplete bone marrow recovery (CRi) or nodular partial remission (nPR) at 27.2 months was not reached (Fig. 2d) [59].

Responses of venetoclax treatment were durable, and a majority of the patients showed a reduction in absolute lymphocyte count, lymph node lesion diameter, and bone marrow infiltrate at a median of 0.3 months of treatment. Management of the tumor lysis syndrome occurred using prophylaxis in 6 patients; none of them reached clinical TLS. Hematologic adverse effects of higher grade (grade ≥3) were neutropenia (42%), anemia (25%), and thrombocytopenia (20%). The results of this pivotal trial led to FDA approval of venetoclax in April 2016 for the treatment of previously treated CLL patients with del(17p) [60•].

M14-032 recruited relapsed/refractory patients after previous treatment with ibrutinib or idelalisib. The ORR in the ibrutinib pretreated group was 65%, the 12-month PFS was 75%. In the idelalisib-pretreated group, the ORR was 67%, and an estimated 1-year progression-free survival of 79% was found [61]. Most common grade 3 or 4 adverse effects were neutropenia (51%), thrombocytopenia (29%), and anemia (29%). Of 91, 17 patients died because of progressive disease [61]. Importantly, venetoclax induced deep remissions with MRD negativity in contrast to treatment with BCR pathway inhibitors [62]. No incidence of tumor lysis syndrome (TLS) was observed.

Since the application of venetoclax induces a rapid reduction of tumor cells with abrupt onset within 6–8 h after dosing, TLS is a major risk issue in clinical care, owing to the high potency of the drug. Dimension of TLS, resulting in rapid cell death, is dependent on tumor mass [63, 64], comorbidities such as renal function, and treatment dose [63]. Quick release of metabolites into the blood stream destabilizes renal excretion, which causes hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, following acute renal failure and cardiac events of life-threatening potential. For this reason, patients in early treatment phase should be monitored closely for TLS. Prophylaxis of TLS including hydration, diuresis, monitoring of electrolytes, and prevention of hyperuricemia should be performed according to its severity and treatment following the guidelines on risk assessment and prophylaxis of TLS [65].

Despite high rates of durable remission in patients, continuous daily treatment with venetoclax induces secondary resistance. Venetoclax resistance was shown to be implicated with complex clonal shifts [66]. Using an in vitro genome-scale screen, Güézé et al. identified regulators of lymphoid transcription and cellular metabolism as resistance drivers. Confirmation in CLL patient cells with early progressive disease uncovered MCL-1 overexpression and AMPK signaling responsible for venetoclax resistance [66]. Whole exome sequencing of 8 CLL patients with dysfunctional TP53 and a median time of 15.4 months from initial treatment until progression uncovered heterogeneous clonal evolution under venetoclax treatment. Two patients developed a BTG1 mutation; 3 patients had a homozygous deletion affecting CDKN2A/B, one BRAF mutation, and an amplification of CD274 were deciphered [67]. Very recently, another recurrent mutation was reported by comparison of paired pre-venetoclax and progression samples after long-term treatment. Seven of 15 patients carried a novel Gly101Val mutation in BCL2, which was selected at progression after 19 to 42 months, but not at the beginning of treatment [68]. The authors showed that Gly101Val reduces the affinity of BCL2 for venetoclax by 180-fold. In a second report, Tausch et al. identified the BCL2Gly101Val mutation and an additional D103Y mutation in 3 of 4 venetoclax progressive patients [69]. These data demonstrate a selection of cell clones which acquire mutations under selection pressure of venetoclax. Especially, long-term treatment is prone to drive the evolution of resistant tumor cells. Clinical trials therefore aimed at time-limited, highly effective combination strategies to obtain deep remissions and to prevent secondary resistance generation.

The MURANO trial was the pivotal trial establishing time-limited therapy with venetoclax and led to the extension of the FDA and EMA approval of venetoclax and rituximab for all R/R CLL patients, regardless their del(17p) status. This phase III trial aimed to test efficacy and safety of the combination venetoclax and rituximab (VR) in order to avoid secondary resistance generation. In brief, 194 rel/ref. patients were treated 2 years with venetoclax and received 6 cycles of rituximab, compared with 6 cycles of bendamustine-rituximab (BR). At 24 months, PFS was estimated to be 84.9% compared with 36.3%, respectively. MRD negativity, OS, and ORR were impressively improved. After termination of venetoclax, follow-up at 3 years demonstrated an excellent benefit of
VR against BR in regard to PFS (71.4% vs. 15.2%) with slightly enriched adverse effects (neutropenia 57.7% vs. 38.8%) in the VR group [70].

In May 2019, the FDA approved venetoclax for front line CLL treatment based on the CLL14 study [71]. Four hundred thirty-two patients with previously untreated CLL and coexisting medical conditions were randomized to venetoclax and obinutuzumab (Ven + G) or obinutuzumab + chlorambucil (GCib). After a follow-up of 24 months, the Kaplan-Meier estimate of the percentage of PFS was significantly higher in the Ven + G group than in the GCib group (88.2% vs. 64.1%); PFS was still significantly improved at 28.1 months in the Ven + G group (30 primary end-points counted vs. 77). Moreover, patients with TP53 deletion, mutations, or unmutated IGHV had a significant benefit as well. Adverse effects as grade 3 or 4 neutropenia or infections were comparable in both of the arms [71].

**Combination Trials of BCR Inhibitors and BCL2 Inhibitors**

Venetoclax and ibrutinib have two different modes of action, and preclinical studies in human and mouse CLL cells demonstrated synergistic activity [72, 73]. Efficacy profiles of the two drugs behave also complementarily, since ibrutinib-dependent lymphocytosis leads to clearance of tumor cells from lymph nodes and mobilizes them into the peripheral lymph nodes.
In contrast to ibrutinib, venetoclax-induced apoptosis has prominent efficacy in the blood and marrow. Moreover, venetoclax is able to induce MRD negativity, which rarely occurred with ibrutinib treatment. Thus, the CAPTIVATE trial analyzed the combination of ibrutinib and venetoclax in 163 treatment naïve CLL. In the combination arm, patients received single-agent ibrutinib for the first 3 cycles (cycle = 28 days) followed by an ibrutinib plus venetoclax combination for at least 12 cycles. After MRD negativity, ibrutinib was continued daily. Early analysis shows a CR rate of 100% as well as MRD negativity of 82% [74].

Following a similar strategy, the ongoing phase II CLARITY trial aims to determine therapeutic activity and safety of this combination with the intention to stop therapy. An interim result demonstrated that the primary endpoint, MRD negativity, was achieved in 28/53 (53%) patients in PB and 19/28 (36%) in bone marrow. Impressively, 89% patients responded, and CR rate was 51%, ongoing with high tolerance and acceptable adverse events [75].

Another phase II study of combined ibrutinib and venetoclax involved 80 naïve high-risk and older patients. Patients carried at least a high-risk feature (del(TP53) or TP53mut, del(11q), or unmutated IGHV). Impressive responses across all subgroups in the subset of patients who completed 12 cycles of treatment with 88% of complete remission and 61% remission with undetectable MRD [76].

Further trials which are still ongoing are the NCT02756897 (combined treatment of ibrutinib and venetoclax), NCT03226301 and NCT03045328 (combined treatment of ibrutinib and venetoclax in R/R patients), NCT03128879 (high risk CLL), and NCT03513562 (patients with ibrutinib-resistant mutations).

Further development aiming at deep responses are triple therapies with ibrutinib, venetoclax, and obinutuzumab (NCT02427451, NCT02758665/CLL2-GIVe, and NCT02950051/CLL13). NCT02427451 was reported in 2018 by Rogers et al. In the phase 1b study, a small cohort of 12 R/R patients received 4 doses of obinutuzumab up to 8 courses. In parallel, they were treated with ibrutinib daily starting on course 2 and venetoclax, starting at course 3 for a total of 14 courses. To minimize risk of TLS, ibrutinib and venetoclax were introduced sequentially. The overall response rate was 92% with 6 patients being MRD negative at the end of treatment. Notably, no clinical or laboratory TLS occurred. Of the patients, 33% sustained grade ≥ 3 neutropenia, which is comparable with single treatment of venetoclax [77].

The phase 2 CLL2 BAG trial aimed to first reduce tumor cells using bendamustine followed by maintenance therapy by obinutuzumab and venetoclax up to 24 months. A total of 66 patients were enrolled and treated with the sequential triple T concept. First, the 63 patients (34 treatment naïve and 29 R/R) received bendamustine for the debulking of tumor cells. After two 28-day cycles, maintenance therapy with obinutuzumab and venetoclax in a weekly dose escalation was proceeded. To date, most common adverse effects were neutropenia (44%), infections (14%), and thrombocytopenia (9%) [78].

The primary objective of the multicenter phase II CLL2-GIVe trial aims to evaluate the efficacy of ibrutinib and venetoclax and obinutuzumab in physically fit or unfit, previously untreated patients with del(17p) or TP53 mutation [79]. Currently, all 41 high-risk patients have been recruited, and the primary endpoint (CR rate after 12 cycles of treatment) will be available in Q2 2020.

The phase III CLL13 trial (GAIA), an international four arm study for physically fit patients, is testing chemotherapy-free frontline therapy for previously untreated patients without del(17p). The trial is fully enrolled and tested with standard chemotherapy (FCR/BR), venetoclax plus rituximab (RVe), venetoclax plus obinutuzumab (GVe) and venetoclax plus ibrutinib, and obinutuzumab (GIVe) with MRD and PFS as co-primary endpoints [80].

**Conclusion**

Ibrutinib and venetoclax monotherapy have been initially licensed based on remarkable single-agent efficacy and favorable tolerability profile, including chemo-refractory and genetic high-risk subgroups of CLL. However, resistance due to specific mechanisms (e.g., BTK, PLCg2, and BCL2 mutations) is emerging indicating the need to develop time-limited combinations. Approved combination treatments such as venetoclax or ibrutinib with obinutuzumab show high response rates and long remission durations. It is possible that these strategies may lead to long-term remission and potential cure of CLL. Comparison of sequential treatment with combinations and discontinuation of therapy are important aspects which need to be investigated.

Based on the high rate of deep responses and long remission durations combined with good tolerability, venetoclax-based combinations with BTK inhibitors or triple combinations are very likely the future of CLL treatment; however, the approaches are still experimental and require more clinical data before adapted in general practice.

**Funding Information** Open Access funding provided by Projekt DEAL.

**Compliance with Ethical Standards**

**Conflict of Interest** Annika Scheffold declares that she has no conflict of interest.

Stephan Stilgenbauer has received fees for consulting, drug/equipment supplied by the entity, travel paid by the entity, and provided writing assistance for AbbVie, AstraZeneca, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Novartis, Pharmacyclics, and Sunesis Pharmaceuticals.
Of major importance

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance
• Of major importance

1. Gribben JG. Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther. 2010;10(9):1389–94. https://doi.org/10.1586/era.10.127.

2. Zenz T, Mertens D, Kuppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37–50. https://doi.org/10.1038/nrc2764.

3. Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247–54. https://doi.org/10.1182/blood-2014-01-456150.

4. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6. https://doi.org/10.1056/NEJM200012283432602.

5. Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014;124(26):3841–9. https://doi.org/10.1182/blood-2014-07-586826.

6. Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756–65. https://doi.org/10.1200/JCO.2009.26.4556.

7. Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–42. https://doi.org/10.1016/S1470-2045(16)30051-1.

8. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–15. https://doi.org/10.1182/blood-2015-06-651125.

9. Catovsky D, Richards S, Matutes E, Oscier D, Dyer M, Bezares RF, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet. 2007;370(9583):230–9. https://doi.org/10.1016/S0140-6736(07)61125-8.

10. O’Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukaemia. J Clin Oncol. 2001;19(5):1414–20. https://doi.org/10.1200/JCO.2001.19.5.1414.

11. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukaemias. Blood. 1993;82(6):1580–9. https://doi.org/10.1182/blood.199306058675. Accessed July 31, 2019.

12. Boross P, Leusen JHW. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;6(6):676–90. http://www.ncbi.nlm.nih.gov/pubmed/23226614. Accessed July 31, 2019.

13. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74. https://doi.org/10.1016/S0140-6736(10)61381-5.

14. Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs. 2009;18(4):491–500. https://doi.org/10.1517/13543780902386279.

15. Hillmen P, Robak T, Janssens A, Babu KG, Kloezcko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873–83. https://doi.org/10.1016/ S0140-6736(15)60027-7.

16. Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2017;58(5):1084–93. https://doi.org/10.1080/10428194.2016.1235356.

17. Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, et al. Ofatumumab in poor-prognosis chronic lymphocytic leukaemia: a phase IV, non-interventional, observational study from the European research initiative on chronic lymphocytic leukaemia. Haematologica. 2015;100(4):511–6. https://doi.org/10.3324/haematol.2014.118158.

18. Alduaij W, Iovanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117(17):4519–29. https://doi.org/10.1182/blood-2010-07-296913.

19. Cartron G, Watier H. Obinutuzumab: what is there to learn from clinical trials? Blood. 2017;130(5):581–9. https://doi.org/10.1182/ blood-2017-03-771832.

20. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10. https://doi.org/10.1056/NEJMoa1313984.

21. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci. 2010;107(29):13750–6. https://doi.org/10.1073/pnas.1004594107.

22. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810–7. https://doi.org/10.1182/blood-2013-09-527853.

23. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):
32–42. https://doi.org/10.1056/NEJMoa1215637. Phase I/IIb trial for the approval of ibrutinib for previously treated patients.

24. O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910–9. https://doi.org/10.1182/blood-2017-10-810044.

25. Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031–42. https://doi.org/10.1182/blood-2018-08-870238.

26. Fraser G, Cramer P, Demirkar F, Silva RS, Groscik S, Pristupa A, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 2019;33(4):969–80. https://doi.org/10.1038/s41375-018-0276-9.

27. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37. https://doi.org/10.1056/NEJMoa1510088.

28. Shanafelt TD, Wang V, Kay NE, et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019;381(5):432–443. https://doi.org/10.1056/NEJMoa1817073.

29. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemomunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28. https://doi.org/10.1056/NEJMoa1812836.

30. Moreno C, Greil R, Demirkar F, Tedeschi A, Anz B, Larrat L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukemia (iLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. https://doi.org/10.1016/S1470-2045(18)30788-5.

31. Woyach JA, Ruppert AS, Guinn D, Lehan A, Blachly JS, Lozanski A, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437–43. https://doi.org/10.1200/JCO.2016.70.2282.

32. Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2266–94. https://doi.org/10.1056/NEJMoa1400209.

33. First description of the BTK C481S mutation mediating resistance to ibrutinib.

34. Walliser C, Hermkes E, Schade A, Wiese S, Deinzer J, Zapatka M, et al. The phospholipase Cγ2 mutants R665W and L845F identified in ibrutinib-resistant chronic lymphocytic leukemia patients are hypersensitive to the rho GTPase Rac2 protein. J Biol Chem. 2016;291(42):22136–48. https://doi.org/10.1074/jbc.M116.746842.

35. Woyach JA, Ruppert AS, Guinn D, Lehan A, Blachly JS, Lozanski A, et al. BTKC481S -mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437–43. https://doi.org/10.1200/JCO.2016.70.2282.

36. Furman RR, Shamaran JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007. https://doi.org/10.1056/NEJMoa1315226.

37. Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297–311. https://doi.org/10.1016/S1470-2045(16)30671-4.

38. Shamaran JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37(16):1391–402. https://doi.org/10.1200/JCO.18.01460.
64. Crombie J, Davids MS. Venetoclax for the treatment of patients
with chronic lymphocytic leukemia. Haematologica. 2019;2019.222588. https://doi.org/10.3324/haematol.2019.222588.

65. Tausch E, Close W, Dolnik A, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342–53. https://doi.org/10.1158/2159-8290.CD-18-1119.

66. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80(2):293–109181. Accessed September 19, 2017.

67. Kipps TJ, Erada T, Grosicki S, Catalanzo J, Cosolo W, Dyagil I, et al. Phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(10):2826–33. https://doi.org/10.3109/10428194.2015.1030638.

68. Roberts AW, Davids MS, Page JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22. https://doi.org/10.1056/NEJMoa1513257. FDA/EMA approval of venetoclax for patients with previously treated CLL.

69. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed/refractory chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase 2 pivotal trial. J Clin Oncol. 2018;36(19):1973–80. https://doi.org/10.1200/JCO.2017.76.6840.

70. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed/refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78. https://doi.org/10.1016/S1470-2045(16)30019-5. Pivotal trial of FDA approval of venetoclax in previously treated CLL patients with del(17p).

71. Jones JA, Mato AR, Wierda WG, Davids MS, Chiori M, Cheson BD, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65–75. https://doi.org/10.1016/S1470-2045(17)30090-9.

72. Coutre S, Chiori M, Furman RR, Eradat H, Heffner L, Jones JA, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018;131(15):1704–11. https://doi.org/10.1182/blood-2017-06-781313.

73. Cheson BD, Heitner Enschede S, Cerri E, Desai M, Potluri J, Lamanna N, et al. Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents. Oncologist. 2017;22(11):1283–91. https://doi.org/10.1634/theoncologist.2017-0055.

74. Crombie J, Davids MS. Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Future Oncol. 2017;13(4):1223–32. https://doi.org/10.2217/fon-2017-0031.

75. Howard SC, Jones DP, Pui C-H. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54. https://doi.org/10.1056/NEJMra0904569.

76. Guíez R, Liu VM, Rosebrock D, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019. https://doi.org/10.1016/j.ccell.2019.08.005.

77. Herling CD, Abedpour N, Weiss J, Schmitz A, Jachimowicz RD, Mertel O, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018;9(1):727. https://doi.org/10.1038/s41467-018-03170-7.

78. Blombery P, Anderson MA, Gong J, Thijsen R, Birkshaw RW, Thompson ER, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342–53. https://doi.org/10.1158/2159-8290.CD-18-1119.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.